These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. Conti M; Richter W; Mehats C; Livera G; Park JY; Jin C J Biol Chem; 2003 Feb; 278(8):5493-6. PubMed ID: 12493749 [No Abstract] [Full Text] [Related]
8. cAMP-Specific phosphodiesterase-4 enzymes in the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP signaling. Houslay MD; Baillie GS; Maurice DH Circ Res; 2007 Apr; 100(7):950-66. PubMed ID: 17431197 [TBL] [Abstract][Full Text] [Related]
9. Expression, intracellular distribution and basis for lack of catalytic activity of the PDE4A7 isoform encoded by the human PDE4A cAMP-specific phosphodiesterase gene. Johnston LA; Erdogan S; Cheung YF; Sullivan M; Barber R; Lynch MJ; Baillie GS; Van Heeke G; Adams DR; Huston E; Houslay MD Biochem J; 2004 Jun; 380(Pt 2):371-84. PubMed ID: 15025561 [TBL] [Abstract][Full Text] [Related]
10. Crystal structure of phosphodiesterase 9 shows orientation variation of inhibitor 3-isobutyl-1-methylxanthine binding. Huai Q; Wang H; Zhang W; Colman RW; Robinson H; Ke H Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9624-9. PubMed ID: 15210993 [TBL] [Abstract][Full Text] [Related]
11. Behavioural effects of selective PDE4 inhibitors in relation to inhibition of catalytic activity and competition for [3H]rolipram binding. Kapui Z; Bence J; Boronkay E; Mikus E; Urbán Szabó K; Baranyi A; Arányi P Neurobiology (Bp); 1999; 7(1):71-3. PubMed ID: 10746252 [No Abstract] [Full Text] [Related]
12. Characterization of phosphodiesterase 4 in guinea-pig macrophages: multiple activities, association states and sensitivity to selective inhibitors. Kelly JJ; Barnes PJ; Giembycz MA Br J Pharmacol; 1998 May; 124(1):129-40. PubMed ID: 9630352 [TBL] [Abstract][Full Text] [Related]
13. Comparison of recombinant human PDE4 isoforms: interaction with substrate and inhibitors. Saldou N; Obernolte R; Huber A; Baecker PA; Wilhelm R; Alvarez R; Li B; Xia L; Callan O; Su C; Jarnagin K; Shelton ER Cell Signal; 1998 Jun; 10(6):427-40. PubMed ID: 9720765 [TBL] [Abstract][Full Text] [Related]
14. Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma. Deng YM; Xie QM; Tang HF; Sun JG; Deng JF; Chen JQ; Yang SY Eur J Pharmacol; 2006 Oct; 547(1-3):125-35. PubMed ID: 16956605 [TBL] [Abstract][Full Text] [Related]
15. Identification of inhibitor binding sites of the cAMP-specific phosphodiesterase 4. Richter W; Unciuleac L; Hermsdorf T; Kronbach T; Dettmer D Cell Signal; 2001 Apr; 13(4):287-97. PubMed ID: 11306246 [TBL] [Abstract][Full Text] [Related]
16. Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors. Castro A; Jerez MJ; Gil C; Martinez A Med Res Rev; 2005 Mar; 25(2):229-44. PubMed ID: 15514991 [TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase 4 regulation of cyclic AMP in pulmonary remodelling: potential roles for isoform selective inhibitors. Shepherd MC Pulm Pharmacol Ther; 2006; 19(1):24-31. PubMed ID: 16046159 [No Abstract] [Full Text] [Related]
18. New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung disease. Barnette MS; Underwood DC Curr Opin Pulm Med; 2000 Mar; 6(2):164-9. PubMed ID: 10741778 [TBL] [Abstract][Full Text] [Related]
20. The cAMP-specific phosphodiesterase PDE4D3 is regulated by phosphatidic acid binding. Consequences for cAMP signaling pathway and characterization of a phosphatidic acid binding site. Grange M; Sette C; Cuomo M; Conti M; Lagarde M; Prigent AF; Némoz G J Biol Chem; 2000 Oct; 275(43):33379-87. PubMed ID: 10938092 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]